Skip to main content
SpringerLink
Log in

Inhaled Corticosteroids for COPD: Are Inhaled Corticosteroids Required in the Management of COPD?

  • Chapter
  • First Online:
Chronic Obstructive Pulmonary Disease

  • 3157 Accesses

Abstract

Inhaled corticosteroids (ICSs) strongly suppress airway inflammation and are widely used as the first drugs of choice for the treatment of bronchial asthma. Chronic obstructive pulmonary disease (COPD) is also an inflammatory disease of the airway, but because the type of inflammation in COPD differs from the type of inflammation in asthma and because pathology that diminishes the effectiveness of steroids is postulated in COPD, the therapeutic effect of ICSs in COPD is limited. In fact, there are many negative opinions in regard to the preventive effect of ICSs on the progression of COPD and in regard to their effectiveness in lowering mortality. Although ICS effectiveness in preventing exacerbations and effectiveness in preventing decreased quality of life (QOL) have been reported, it has also been reported that no difference in exacerbation-preventing effect was observed when the results of treatment with ICS/long-acting β agonist (LABA) and long-acting muscarinic antagonist (LAMA) were compared, and that when ICSs were gradually discontinued in COPD patients being treated with ICS/LABA/LAMA, the results showed no increase in exacerbation frequency. When selecting COPD patients for treatment with ICSs, it is necessary to consider not just the benefits of treatment, but overtreatment, increased cost, and risk of pneumonia as well.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011). Global Initiative for Chronic Obstructive Lung Disease, Inc; 2011.

    Google Scholar 

  2. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.

    Article  CAS  PubMed  Google Scholar 

  4. Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev. 2012;7:CD002991. doi:10.1002/14651858.

    Google Scholar 

  5. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest. 2010;137:318–25. doi:10.1378/chest.09-1305.

    Article  CAS  PubMed  Google Scholar 

  6. Mehuys E, Boussery K, Adriaens E, Van Bortel L, De Bolle L, Van Tongelen I, et al. COPD management in primary care: an observational, community pharmacy-based study. Ann Pharmacother. 2010;44:257–66. doi:10.1345/aph.1M481.

    Article  PubMed  Google Scholar 

  7. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids—implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8:e75221. doi:10.1371/journal.pone.0075221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378:1015–26. doi:10.1016/S0140-6736(11)60988-4.

    Article  CAS  PubMed  Google Scholar 

  9. Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghè B, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax. 1998;53:583–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med. 1996;153:616–21.

    Article  CAS  PubMed  Google Scholar 

  11. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med. 2005;99:1494–500.

    Article  PubMed  Google Scholar 

  12. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:587–95. doi:10.2147/COPD.S32765.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967–76.

    Article  CAS  PubMed  Google Scholar 

  14. Szulakowski P, Crowther AJ, Jiménez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:41–50.

    Article  CAS  PubMed  Google Scholar 

  15. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148:245–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139:359–70.

    Article  CAS  PubMed  Google Scholar 

  17. Robertson AS, Gove RI, Wieland GA, Burge PS. A double-blind comparison of oral prednisolone 40 mg/day with inhaled beclomethasone dipropionate 1500 ug/day in patients with adult onset chronic obstructive airways disease. Eur J Respir Dis Suppl. 1986;146:565–9.

    CAS  PubMed  Google Scholar 

  18. Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax. 1990;45:112–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Auffarth B, Postma DS, de Monchy JG, van der Mark TW, Boorsma M, Koëter GH. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax. 1991;46:372–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Thompson AB, Mueller MB, Heires AJ, Bohling TL, Daughton D, Yancey SW, et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis. 1992;146:389–95.

    Article  CAS  PubMed  Google Scholar 

  21. Kerstjens HA, Brand PL, Hughes MD, Robinson NJ, Postma DS, Sluiter HJ, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992;327:1413–9.

    Article  CAS  PubMed  Google Scholar 

  22. Watson A, Lim TK, Joyce H, Pride NB. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest. 1992;101:350–5.

    Article  CAS  PubMed  Google Scholar 

  23. Wempe JB, Postma DS, Breederveld N, Kort E, van der Mark TW, Koëter GH. Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease. Thorax. 1992;47:616–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. Thorax. 1993;48:309–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest. 1995;108:1568–71.

    Article  CAS  PubMed  Google Scholar 

  26. Renkema TE, Schouten JP, Koëter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest. 1996;109:1156–62.

    Article  CAS  PubMed  Google Scholar 

  27. Boothman-Burrell D, Delany SG, Flannery EM, Hancox RJ, Taylor DR. The efficacy of inhaled corticosteroids in the management of non asthmatic chronic airflow obstruction. N Z Med J. 1997;110:370–3.

    CAS  PubMed  Google Scholar 

  28. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997;155:542–8.

    Article  CAS  PubMed  Google Scholar 

  29. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax. 1998;53:477–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998;351:773–80.

    Article  CAS  PubMed  Google Scholar 

  31. Rutgers SR, Koëter GH, van der Mark TW, Postma DS. Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5′-monophosphate in COPD. Am J Respir Crit Care Med. 1998;157:880–6.

    Article  CAS  PubMed  Google Scholar 

  32. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1635–9.

    Article  CAS  PubMed  Google Scholar 

  33. Nishimura K, Koyama H, Ikeda A, Tsukino M, Hajiro T, Mishima M, et al. The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest. 1999;115:31–7.

    Article  CAS  PubMed  Google Scholar 

  34. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340:1948–53.

    Article  CAS  PubMed  Google Scholar 

  35. Senderovitz T, Vestbo J, Frandsen J, Maltbaek N, Nørgaard M, Nielsen C, et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med. 1999;93:715–8.

    Article  CAS  PubMed  Google Scholar 

  36. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–23.

    Article  CAS  PubMed  Google Scholar 

  37. Weiner P, Weiner M, Rabner M, Waizman J, Magadle R, Zamir D. The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. J Intern Med. 1999;245:83–9.

    Article  CAS  PubMed  Google Scholar 

  38. Weir DC, Bale GA, Bright P, Sherwood BP. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy. 1999;29 Suppl 2:125–8.

    Article  CAS  PubMed  Google Scholar 

  39. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902–9.

    Article  Google Scholar 

  40. Ferreira IM, Hazari MS, Gutierrez C, Zamel N, Chapman KR. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone. Am J Respir Crit Care Med. 2001;164:1012–5.

    Article  CAS  PubMed  Google Scholar 

  41. Loppow D, Schleiss MB, Kanniess F, Taube C, Jörres RA, Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med. 2001;95:115–21.

    Article  CAS  PubMed  Google Scholar 

  42. Mirici A, Bektas Y, Ozbakis G, Erman Z. Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease: a randomised, double-blind, Placebo-Controlled Clinical Trial. Clin Drug Invest. 2001;21:835–42.

    Article  CAS  Google Scholar 

  43. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165:1592–6.

    Article  PubMed  Google Scholar 

  44. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084–91.

    Article  PubMed  Google Scholar 

  45. Thompson WH, Carvalho P, Souza JP, Charan NB. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD. Lung. 2002;180:191–201.

    Article  CAS  PubMed  Google Scholar 

  46. Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax. 2002;57:694–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–56. Erratum in: Lancet. 2003; 361:1660.

    Article  CAS  PubMed  Google Scholar 

  48. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–9.

    Article  CAS  PubMed  Google Scholar 

  49. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834–43.

    Article  CAS  PubMed  Google Scholar 

  50. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81.

    Article  CAS  PubMed  Google Scholar 

  51. van Grunsven P, Schermer T, Akkermans R, Albers M, van den Boom G, van Schayck O. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respir Med. 2003;97:1303–12.

    Article  PubMed  Google Scholar 

  52. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760–5.

    Article  PubMed  Google Scholar 

  53. Yildiz F, Basyigit I, Yildirim E, Boyaci H, Ilgazli A. Does addition of inhaled steroid to combined bronchodilator therapy affect health status in patients with COPD? Respirology. 2004;9:352–5.

    Article  PubMed  Google Scholar 

  54. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60:193–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. John M, Bosse S, Oltmanns U, Schumacher A, Witt C. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med. 2005;99:1418–24.

    Article  PubMed  Google Scholar 

  56. GlaxoSmithKline. A double/blind, randomised, controlled, three parallel group, multicenter study to compare the acute effects of inhaled Flixotide/Salmeterol vs. Decortin/Flixotide/Salmeterol vs. Salmeterol in patients with COPD. 2005. http://www.gsk-clinicalstudyregister.com/study/FCO30002?study_ids=FCO30002#rs. Accessed 9 Dec 2015.

  57. GlaxoSmithKline. A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg twice daily, 500mcg twice daily, and placebo twice daily via the DISKUS® inhaler in subjects with chronic obstructive pulmonary disease (COPD). 2005. http://www.gsk-clinicalstudyregister.com/study/FLTA3025?study_ids=FLTA3025#rs. Accessed 9 Dec 2015.

  58. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007;62:938–43.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Calverley PM, Rennard S, Nelson HS, Karpel JP, Abbate EH, Stryszak P, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9:73. doi:10.1186/1465-9921-9-73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:1207–14. doi:10.1164/rccm.200709-1356OC.

    Article  CAS  PubMed  Google Scholar 

  61. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151:517–27.

    Article  PubMed  Google Scholar 

  62. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103:542–51. doi:10.1016/j.rmed.2008.11.003.

    Article  PubMed  Google Scholar 

  63. Shaker SB, Dirksen A, Ulrik CS, Hestad M, Stavngaard T, Laursen LC, et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD. 2009;6:104–11. doi:10.1080/15412550902772593.

    Article  PubMed  Google Scholar 

  64. Guenette JA, Raghavan N, Harris-McAllister V, Preston ME, Webb KA, O’Donnell DE. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respir Med. 2011;105:1836–45. doi:10.1016/j.rmed.2011.08.021.

    Article  PubMed  Google Scholar 

  65. Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012;7:73–86. doi:10.2147/COPD.S29444.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Suissa S. Lung function decline in COPD trials: bias from regression to the mean. Eur Respir J. 2008;32:829–31. doi:10.1183/09031936.00103008.

    Article  CAS  PubMed  Google Scholar 

  67. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 1999;54:7–14.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59–65.

    Article  CAS  PubMed  Google Scholar 

  69. De Coster DA, Jones M, Thakrar N. Beclometasone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;10:CD009769. doi:10.1002/14651858.

    Google Scholar 

  70. Jones PW. Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J. 1994;7:55–62.

    Article  CAS  PubMed  Google Scholar 

  71. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–37. doi:10.1183/09031936.00128914.

    Article  CAS  PubMed  Google Scholar 

  72. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20(4):819–25.

    Article  CAS  PubMed  Google Scholar 

  73. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009;136:1029–38. doi:10.1378/chest.09-0821.

    Article  CAS  PubMed  Google Scholar 

  74. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–26. doi:10.2147/COPD.S84436.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D’Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51–60. doi:10.1016/S2213-2600(12)70052-8.

    Article  CAS  PubMed  Google Scholar 

  76. Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109:870–81. doi:10.1016/j.rmed.2015.04.018.

    Article  PubMed  Google Scholar 

  77. Horita N, Miyazawa N, Tomaru K, Inoue M, Kaneko T. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: a systematic review and meta-analysis. Respirology. 2015;20:1153–9. doi:10.1111/resp.12603.

    Article  PubMed  Google Scholar 

  78. Tricco AC, Strifler L, Veroniki AA, Yazdi F, Khan PA, Scott A, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5:e009183. doi:10.1136/bmjopen-2015-009183.

    Article  PubMed  PubMed Central  Google Scholar 

  79. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166:1358–63.

    Article  PubMed  Google Scholar 

  80. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8:93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60:480–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. O’Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med. 2001;164:365–71.

    Article  PubMed  Google Scholar 

  83. Kunz LI, Postma DS, Klooster K, Lapperre TS, Vonk JM, Sont JK, et al. Relapse in FEV1 decline after steroid withdrawal in COPD. Chest. 2015;148:389–96. doi:10.1378/chest.14-3091.

    Article  PubMed  Google Scholar 

  84. Rossi A, van der Molen T, del Olmo R, Papi A, Wehbe L, Quinn M, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44:1548–56. doi:10.1183/09031936.00126814.

    Article  CAS  PubMed  Google Scholar 

  85. Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77. doi:10.1186/1465-9921-15-77.

    PubMed  PubMed Central  Google Scholar 

  86. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–94. doi:10.1056/NEJMoa1407154.

    Article  PubMed  CAS  Google Scholar 

  87. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:171–5.

    Article  CAS  PubMed  Google Scholar 

  88. Monsó E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995;152:1316–20.

    Article  PubMed  Google Scholar 

  89. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.

    Article  CAS  PubMed  Google Scholar 

  90. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162–6.

    Article  CAS  PubMed  Google Scholar 

  91. Di Santostefano RL, Sampson T, Le HV, Hinds D, Davis KJ, Bakerly ND. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One. 2014;9:e97149. doi:10.1371/journal.pone.0097149.

    Article  CAS  Google Scholar 

  92. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115. doi:10.1002/14651858.CD010115.

    Google Scholar 

  93. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219–29. doi:10.1001/archinternmed.2008.550.

    Article  PubMed  Google Scholar 

  94. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:2407–16. doi:10.1001/jama.2008.717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Dong YH, Chang CH, Lin Wu FL, Shen LJ, Calverley PM, Löfdahl CG, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145:1286–97.

    Article  CAS  PubMed  Google Scholar 

  96. Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009;374:712–9. doi:10.1016/S0140-6736(09)61250-2.

    Article  CAS  PubMed  Google Scholar 

  97. Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306. doi:10.1136/bmj.f3306.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–36. doi:10.1136/thoraxjnl-2012-202872.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001–6. doi:10.1016/j.amjmed.2010.06.019.

    Article  CAS  PubMed  Google Scholar 

  100. Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med. 2009;122:472–8. doi:10.1016/j.amjmed.2008.09.048.

    Article  CAS  PubMed  Google Scholar 

  101. O’Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106:1487–93. doi:10.1016/j.rmed.2012.07.011.

    Article  PubMed  Google Scholar 

  102. Flynn RW, MacDonald TM, Hapca A, MacKenzie IS, Schembri S. Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis. Respir Res. 2014;15:141. doi:10.1186/s12931-014-0141-y.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol. 2002;54:59–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int. 2003;14:179–90.

    CAS  PubMed  Google Scholar 

  105. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66:699–708. doi:10.1136/thx.2011.160028.

    Article  PubMed  Google Scholar 

  106. Langhammer A, Forsmo S, Lilleeng S, Johnsen R, Bjermer L. Effect of inhaled corticosteroids on forearm bone mineral density: the HUNT study. Norway Respir Med. 2007;101:1744–52.

    Article  PubMed  Google Scholar 

  107. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010;137:1338–44. doi:10.1378/chest.09-2363.

    Article  CAS  PubMed  Google Scholar 

  108. Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009;64:424–9. doi:10.1136/thx.2008.103432.

    Article  CAS  PubMed  Google Scholar 

  109. Cyr MC, Beauchesne MF, Lemière C, Blais L. Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2008;65:40–50.

    Article  CAS  PubMed  Google Scholar 

  110. Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R, et al. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials. 2015;16:267. doi:10.1186/s13063-015-0782-2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48–55. doi:10.1164/rccm.201108-1553OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2015. pii: thoraxjnl-2015-207021. doi: 10.1136/thoraxjnl-2015-207021.

  113. Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014;312:1114–21. doi:10.1001/jama.2014.11432.

    Article  PubMed  CAS  Google Scholar 

  114. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283–9. doi:10.2147/COPD.S30651.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356:1480–5.

    Article  CAS  PubMed  Google Scholar 

  116. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158:1511–7.

    Article  CAS  PubMed  Google Scholar 

  117. Global Initiative for Asthma. Global strategy for asthma management and prevention: online appendix. 2015. http://www.ginasthma.org/local/uploads/files/GINA_Appendix_2015_May19.pdf.

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Kashiwa Tanaka Hospital, Higashi 65 gaiku 1 Koaota 70-1, Kashiwa, Chiba, 277-0803, Japan

    Masayuki Itoh

Authors
  1. Masayuki Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Itoh .

Editor information

Editors and Affiliations

  1. Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan

    Hiroyuki Nakamura

  2. Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan

    Kazutetsu Aoshiba

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Itoh, M. (2017). Inhaled Corticosteroids for COPD: Are Inhaled Corticosteroids Required in the Management of COPD?. In: Nakamura, H., Aoshiba, K. (eds) Chronic Obstructive Pulmonary Disease. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-10-0839-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-0839-9_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-0838-2

  • Online ISBN: 978-981-10-0839-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation